October 04, 2024

Omalizumab Boosts Tolerance to Food Allergens: Study

In a phase 3 trial, 67% of children treated with omalizumab tolerated 600 mg of peanut protein, a dramatic increase over just 7% with placebo, highlighting omalizumab’s potential in managing pediatric food allergies.

Conexiant

October 02, 2024

Breast is Best? New Research Maps the World's Milk Defenses

New research compares human milk antibody levels against infectious pathogens across different income countries, revealing important insights for infant health.

Conexiant

September 30, 2024

Is Dog Ownership Linked to Lower Risk of Crohn's Disease?

Living with a dog during childhood may cut Crohn's disease risk by 38%, according to a new cohort study involving first-degree relatives of Crohn’s patients.

Conexiant

September 27, 2024

Over 3,600 Food Contact Chemicals Found in Humans

Eighty FCCs had properties that warrant further investigation for potential health concerns, such as carcinogenic, mutagenic, and reproductive toxicity.

Conexiant

September 27, 2024

Genetics Play Large Role in Fussy Eating

A single trajectory of food fussiness was modeled, showing an increase from 16 months to 7 years, followed by a slight decline between 7 and 13 years.

Conexiant

September 23, 2024

Cardiovascular Genes Linked to Psoriasis Risk

Genetic markers for heart disease surprisingly linked to 22% higher psoriasis risk, challenging conventional understanding of their relationship.

Conexiant

September 23, 2024

Evaluating Prehabilitation in Gastric Cancer Surgery: A Systematic Review Protocol

Researchers are investigating the impact of prehabilitation, incorporating exercise, nutrition, and psychological support, on recovery and complications in patients undergoing gastric cancer surgery.

Conexiant

September 20, 2024

Lupus, IBD Share Microbiome Features, Study Shows

Microbiome analysis reveals SLE and IBD share up to 33 common short-chain fatty acid-producing enzymes, suggesting potential shared microbial mechanisms in these distinct autoimmune diseases.

Conexiant

September 19, 2024

FDA Rejects Stomach Paralysis Drug

Vanda Pharmaceuticals' drug to treat gastroparesis symptoms, intended for severe nausea and vomiting associated with delayed gastric emptying, has been declined FDA approval.

Reuters